Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial

Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial

Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease recurrence in resected Stage III/IV melanoma patients in a Phase IIb trial. The TL parti...

Full description

Bibliographic Details
Main Authors: Spencer G. Van Decar, Elizabeth L. Carpenter, Alexandra M. Adams, Robert C. Chick, Guy T. Clifton, Alex Stojadinovic, Timothy J. Vreeland, Franklin A. Valdera, Ankur Tiwari, Anne E. O'Shea, Patrick M. McCarthy, Diane F. Hale, Phillip M Kemp Bohan, Annelies T. Hickerson, Jessica L. Cindass, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser Shaheen, Xianzhong Yu, Thomas Wagner, Mark B. Faries, George E. Peoples
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Cancer vaccine
Melanoma
Dendritic cell
Immunotherapy
Personalized medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294224000558

Internet

http://www.sciencedirect.com/science/article/pii/S2468294224000558

Similar Items